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Background: ATAD2 is associated with many cellular processes, such as cell growth, migration and invasion. However,
no studies have been conducted on the molecular biological function of the ATAD2 gene in hepatocellular
carcinoma (HCC).
Methods: The protein and mRNA level expression of ATAD2 was examined in tissues and cell lines. Prognostic
significance was analyzed by the Kaplan-Meier survival method and Cox regression. ATAD2 knockdown was used
to analyze cell proliferation and invasion. The upstream and downstream of ATAD2 was analyzed by RT2 Profiler™
PCR array and luciferasex fluorescence system.
Results: ATAD2 was highly expressed in liver cancer samples and correlated with poor survival. High ATAD2
expression was positively correlated with metastasis (P = 0.005) and was an independent prognostic factor in
HCC (P = 0.001). ATAD2 depletion by RNA interference reduced their capacity for invasion and proliferation and
led to a G1 phase arrest in vitro. Further study revealed that miR-372 was an upstream target of ATAD2 as miR-372 was
bound directly to its 3′ untranslated region (3′ UTR). In addition, ATAD2 knockdown was found to extremely up-regulate
APC expression and down-regulate CTNNA1 at the mRNA level.
Conclusions: The findings demonstrated that miR-372 suppressed the expression of ATAD2, which was highly
expressed in HCC and exerted a proto-oncogene effect in hepatic carcinogenesis. In conclusion, ATAD2 may
promote HCC progression.Background
HCC is the fifth most common malignant tumor
worldwide, with an incidence of approximately 626,000
cases each year [1,2]. In China and Southeast Asia, HCC
is highly associated with viral hepatitis B and cirrhosis [3].
The prognosis of patients with HCC has largely improved
due to extensive advances in surgical techniques and diag-
nostic methods in recent years. However, the long-term
prognosis is still unsatisfactory, largely due to the high
recurrence and invasion rates even after resection (50-70%
at five years) [4,5]. Unfortunately, little is known with
respect to the molecular mechanisms underlying this
aggressive behavior. Therefore, there is great demand to* Correspondence: wugang@mail.cmu.edu.cn
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unless otherwise stated.find a reliable prognostic biomarker, which may help
clinicians predict the characteristics of the malignancy
and decrease the rate of unfavorable outcomes in a
high-risk population.
ATAD2 (ATPase family AAA domain-containing protein
2), a member of the AAA +ATPase family of proteins,
was identified by microarray analysis [6], contains both
a bromodomain and an ATPase domain, and maps to
chromosome 8q24 in a region that is frequently amplified
in cancer [7]. The structure of ATAD2 suggests that it has
functions related to genome regulation, including cell
proliferation, differentiation and apoptosis. Studies have
revealed that ATAD2 is highly expressed in several types
of tumors such as breast cancer, lung cancer, and large
B-cell lymphoma [8-13]. And recently Huang Q et al. has
reported that a novel, highly up-regulated exon-exon junc-
tion was detected in ATAD2 gene by RNA-seq and the. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
Table 1 Distribution of ATAD2 and Clinicopathological








Total cases 129 83 46
Age (years)
≥60 54 34(63.0%) 20(37.0%) 0.782
<60 75 49(65.3%) 26(34.7%)
Gender
Male 106 69(65.1%) 37(34.9%) 0.701
Female 23 14(60.9%) 9(39.1%)
Tumor size
≥ 5cm 83 53(63.9%) 30(36.1%) 0.877
< 5cm 46 30(65.2%) 16(34.8%)
Metastasis
Yes 72 54(75%) 18(25%) 0.005
No 57 29(50.9%) 28(49.1%)
HBsAg status
Positive 73 43(58.9%) 30(41.1%) 0.141
Negative 56 40(71.4%) 16(28.6%)
Tumor
differentiation
WD 54 34(63.0%) 20(37.0%) 0.955
MD 60 39(65.0%) 21(35.0%)
PD 15 10(66.7%) 5(33.3%)
Cirrhosis
Yes 86 58(67.4%) 28(32.6%) 0.298
No 43 25(58.1%) 18(41.9%)
Serum AFP
<200 ng/dl 41 29(70.7%) 12(29.3%) 0.301
≥200 ng/dl 88 54(61.4%) 34(38.6%)
Tumor stage
TNM I+II 42 25(59.5%) 17(40.5%) 0.427
TNM III+IV 87 58(66.7%) 29(33.3%)
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there have been no studies on the gene function and
prognosis associated with ATAD2 in HCC.
In the present study, we detected the expression of
ATAD2 in HCC and matched adjacent non-cancerous
liver tissues. Different methods were used to determine
the relationships between the expression of ATAD2, its
clinical relevance, and the overall survival (OS) after resec-
tion. In addition, the effects of ATAD2 expression on cell
invasion and metastasis were investigated in SMMC7721,
QGY-7701, Bel-7402, PLC5, Huh7, HCCLM3, HepG2,
and LO2 cell lines using small interfering RNAs. Also the
miR-372 was identified as a direct and functional target
for ATAD2 in hepatic carcinogenesis. Therefore, both




Primary tumor samples were obtained from 129 patients
(106 males and 23 females) who were diagnosed with
HCC and had undergone routine hepatic resection in the
First Affiliated Hospital of China Medical University
between January 2006 and December 2009. The follow-up
period for survivors was 5 years. None of the patients had
received preoperative radiotherapy or chemotherapy prior
to surgical resection. The histological diagnosis and differ-
entiation were evaluated independently by two pathologists
according to the WHO classification system [15]. The
clinicopathological features are shown in Table 1. Fresh
specimens were snap-frozen in liquid nitrogen and stored
at −70°C immediately after resection for the extraction of
RNA and protein. The project protocol was approved by
the Institutional Ethics Committee of China Medical
University prior to the initiation of the study. All patients
provided written informed consent for the use of the
tumor tissues for clinical research.
Liver cancer cell lines and cell cultures
The liver cancer cell lines, SMMC7721, QGY-7701,
Bel-7402, PLC5, Huh7, HCCLM3, HepG2, and the normal
liver cell line, LO2, were obtained from the Shanghai Cell
Bank (Shanghai, China). SMMC7721, QGY-7701, Bel-7402
and PLC5 cells were cultured in RPMI-1640 (Invitrogen,
Carlsbad, CA). Huh7, HCCLM3, HepG2 and LO2 cells
were grown in DMEM (Invitrogen). All media were
supplemented with 10% fetal calf serum (Invitrogen) and
100 IU/ml penicillin (Sigma, St. Louis, MO).
RNA preparation and quantitative real-time PCR
Total RNA was extracted according to the manufacturer’s
instructions. RT-qPCR was performed using a SYBR Pre-
mix Ex Taq (TaKaRa) on a Thermal Cycler Dice Real Time
System (TaKaRa) with the following protocol: 30 s at 95°Cfollowed by two-step PCR for 40 cycles of 95°C for 5 s
and 64°C for 30 s. Each reaction was performed as we
previously described [3]. The primer sequences were as









Total protein was extracted from tumor tissues, non-tumor
adjacent tissues and liver cancer cell lines using the Nuclear
and Cytoplasmic Protein Extraction Kit (Beyotime, China).
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by SDS-PAGE and then electrotransferred to PVDF
membranes (Millipore, Billerica, MA, USA). Milk (5%) was
used to block membranes for 2 hours at room temperature.
After blocking, primary antibodies, including ATAD2,
APC, CTNNA1 rabbit polyclonal antibody and GAPDH
mouse polyclonal antibody (both diluted at 1:1000, Sigma,
St. Louis, MO, USA), were incubated with the membranes
overnight at 4°C. The secondary antibodies were then
incubated for 2 hours at room temperature. Protein bands
were identified using an ECL system (Millipore, Bedford,
MA, USA)
Immunohistochemistry
ATAD2 expression was analyzed on paraffin-embedded
specimens from 129 patients. Tissue sections of 4-μm
thickness were deparaffinized in xylene and dehydrated
before antigen retrieval for 5 min with an autoclave.
Hydrogen peroxide (0.3%) was used to block endogenous
peroxidase activity; nonspecific immunoglobulin binding
sites were blocked by normal goat serum for 30 min at
37°C. Tissue sections were incubated with anti-ATAD2
(1:200, Sigma) overnight at 4°C. Biotinylated goat anti-
rabbit immunoglobulin G was used as a secondary antibody
(1:300, Sigma). After washing, the sections were incubated
with streptavidin-biotin conjugated with HRP for 30 min,
and the peroxidase reaction was developed with 3, 3′-di-
aminobenzidine tetrahydrochloride (DAB).
Semi-quantitative assessment and scoring
ATAD2 expression levels were scored semiquantitatively
according to the percent of positively stained cells com-
bined with the staining intensity. Samples were considered
positive for ATAD2 if the nucleus or cytoplasm of the sam-
ple cells presented a positive staining. The percent positivity
was defined as “0” if 0%, “1” if 1-10%, “2” if 11-50%, “3” if
51-80%, and “4” if >80%. The staining intensity was scored
as “0” (no staining), “1” (weakly stained), “2” (moderately
stained) and “3” (strongly stained). Both the percent posi-
tivity and the staining intensity were assessed by two
doubly blinded investigators. The ATAD2 expression
score was calculated from the value of percent positivity
score × the staining intensity score. This value thus ranged
from 0 to 12, and the tumors were classified into the
following: negative (−), score 0; lower expression (1+),
score 1–4; moderate expression (2+), score 5–8; and
strong expression (3+), score 9–12. The immunohisto-
chemical ATAD2 staining was grouped into two categories:
low expression (0/1+) and high expression (2+/3+).
Depletion of ATAD2 by small interfering RNAs
On-TargetPlus SMARTpool siRNA for ATAD2 (No.
LU-017603-00-0002) and On-TargetPlus siControl (D-
001810-01-20) were purchased from Dharmacon. Fortransfections, 24 h after the cells were seeded in a 6-well
plate, they were transfected with ATAD2 siRNA or control
siRNA using DharmaFECT 1 according to the manu-
facturer’s protocol. The mRNA and protein levels were
detected 48 h later.Cell cycle analysis
Huh7 and HCCLM3 cells in 6-well plates were transfected
with ATAD2 siRNA or negative control siRNA. After 48 h
of transfection, cells seeded at a density of 5 × 105 per well
were trypsinized, fixed with 70% ethanol at 4°C, and washed
with PBS. A quantity of 100 μL RNase A was added, and
the mixture was incubated in a 37°C water bath for 30 min.
An additional 400 μL PI staining solution was added and
incubated at 4°C in the dark for 30 min; a computer was
then used to detect and record the red fluorescence upon
excitation at a wavelength of 488 nm.CCK8 and Colony formation assay
Cells were plated in 96-well plates in media containing
10% FBS at approximately 2,000 cells per well, 24 h after
transfection. Then, 10 μl of CCK8 (Thiazolyl Blue) solu-
tion was added to each well and incubated for 1 h at 37°C.
The results were quantified spectrophotometrically using
a test wavelength of 450 nm.
After transfection, logarithmic growth phase cells in
monolayer culture were prepared for the colony formation
assay. Cells were plated in 6-well plates in media contain-
ing 10% FBS at approximately 200 cells per well. Colony
formation was then allowed to proceed for two weeks.
Cells were washed with 1 ml of PBS, fixed, stained with
500 μl of 0.1% crystal violet solution for 20 min, and
finally washed three times with 1 ml of water. The fixed
cell colonies were allowed to air dry. The clone formation
rate was calculated.Cell invasion and migration assay
Huh7 and HCCLM3 cells were infected with ATAD2
siRNA for 48 h. Cells were then seeded onto a synthetic
basement membrane present in the inset of a 24-well
culture plate. In the invasion assay, polycarbonate filters
coated with 50 μL Matrigel (1:9, BD Bioscience) were
placed in a Transwell chamber (Costar). In the migration
assay, no Matrigel was placed in the chambers. Fetal
bovine serum was added to the lower chamber as a
chemoattractant. Cells were then incubated at 37°C
and allowed to invade through the Matrigel barrier for
hours. After incubation, filters were fixed and stained
with 0.1% crystal violet solution. Non-invading cells
were removed using a cotton swab, and invading cells on
the underside of the filter were counted with an inverted
microscope.
Wu et al. BMC Cancer 2014, 14:107 Page 4 of 11
http://www.biomedcentral.com/1471-2407/14/107Real-time polymerase chain reaction gene array
Forty-eight hours after siRNA knockdown, RNA was
extracted from the cells using Trizol (Invitrogen) and
cleaned with the RNeasy_MinEluteTM Cleanup Kit (Qiagen,
Valencia, CA). Subsequently, total RNA was reverse
transcribed using SuperScript III Reverse Transcriptase
(Qiagen), and complementary DNA was amplified by
the polymerase chain reaction (PCR) using 2_Super Array
PCR master mix (Qiagen). Real-time PCR was then per-
formed on each sample with the Human Tumor Metastasis
RT2 ProfilerTM PCR Array (SuperArray Bioscience) in a
Thermal Cycler Dice Real Time System (Takara TP800,
Japan) according to the manufacturer’s instructions. Data
were normalized to GAPDH levels by the 2-ΔΔCt method.
Luciferase assays
293 Tcells were plated into 24-well plates at 80% confluence
24 hours before transfection. A mixture of 200 ng pGL3-3′
UTR, 700 ng pGV214-miR-372, and 100 ng Renilla lu-
ciferase plasmid were transfected into 293 T cells using
Lipofectamine 2000. Firefly and Renilla luciferase activities
were calculated using a dual-luciferase reporter system
(Promega, Madison, WI).
Statistical analysis
SPSS 17.0 software for Windows was used. The association
between ATAD2 expression and HCC patients’ clinico-
pathological features was evaluated by the χ2 test. The
Wilcoxon test was performed to compare data from the
densitometry analysis of mRNA and protein expression.
The Kaplan-Meier method was used to calculate the pa-
tients’ survival by a log-rank test. A Cox repression model
was performed for the univariate and multivariate analysis
of prognostic variables. All P values reported are two-sided,
and P < 0.05 is considered statistically significant.
Results
Expression and Clinical significance of ATAD2 protein
expression in HCC
The median ATAD2 expression level in primary HCCs was
nearly two-fold higher than in non-tumorous livers (median
expression = 0.158 and 0.083, respectively), (P < 0.05
[Wilcoxon signed-rank test]) (Figure 1a). ATAD2 was
overexpressed in 83 of 129 tumor samples (83/129, 64.3%)
according to IHC. The ATAD2 protein appeared to be
expressed in both the nucleus and the cytoplasm of tumor
cells, with stronger expression in the nucleus (Figure 1b).
Compared to the normal cell line LO2, Huh7 and
HCCLM3 cells showed relatively higher levels of ATAD2
expression in seven liver cancer cell lines by Western
blotting (Figure 1c). At the protein level, 6/8 (75%) HCC
samples showed upregulated ATAD2 expression compared
to their adjacent normal liver tissues (Figure 1d).Association of ATAD2 expression with HCC patient
clinical outcome
Patients with high ATAD2 expression had metastases and
poorer prognosis (Table 1). The overall survival was sig-
nificantly lower in patients with high ATAD2 expression
than in patients with low ATAD2 expression (P < 0.05,
Figure 2). In addition, a multivariate analysis demonstrated
that ATAD2 status, the tumor size, metastasis and the AFP
status were significant prognostic factors for HCC patients
(Table 2).
Depletion of ATAD2 inhibits tumor cell growth in liver
cancer cell lines
A significant reduction in the proliferation rate was
observed with the CCK8 assay 2 days after transfection
with ATAD2 siRNA when compared to negative control
siRNA (Figure 3a). Consistent with the CCK8 assay, the
depletion of ATAD2 in Huh7 (Neg. siRNA vs. ATAD2
siRNA: 124 ± 16 vs. 36 ± 10, P < 0.001) and HCCLM3 (Neg.
siRNA vs. ATAD2 siRNA: 102 ± 22 vs. 39 ± 13, P < 0.001)
cells led to a significant reduction in the number and size
of foci (Figure 3b). The DNA content determined using
flow cytometry demonstrated that ATAD2 siRNA transfec-
tion increased the percentage of cells in G1 phase and de-
creased those in the S phase in both cell lines (Figure 4).
Invasive and migratory capacity of liver cancer cells is
decreased by ATAD2 knockdown
Cell invasion and migration assays demonstrated that
the Huh7 and HCCLM3 liver cancer cell lines that were
transfected with ATAD2 siRNA displayed more attenu-
ated invasive and migratory capacities than those of the
negative controls (Figure 5).
The depletion of ATAD2 in Huh7 (control vs. ATAD2
siRNA: 63 ± 11 vs. 33 ± 7, *P < 0.05) and HCCLM3
(control vs. ATAD2 siRNA: 78 ± 14 vs. 32 ± 9, *P < 0.05)
cells led to a significant reduction in invasive cells
(Figure 5a-b). The migration of Huh7 (control vs. ATAD2
siRNA: 80 ± 11 vs. 51 ± 6,*P < 0.05) and HCCLM3
(control vs. ATAD2 siRNA: 70 ± 12 vs. 31 ± 8, *P < 0.05)
cells was also significantly reduced (Figure 5c-d).
ATAD2 regulated APC and CTNNA1 expression in HCC cells
To obtain further insight into the functions of ATAD2 in
HCC cell invasion and metastasis, the mRNA expression
profile of siATAD2-transfected Huh7 cells was compared
with that of si-negative transfected cells using a Human
Tumor Metastasis RT2 Profiler™ PCR Array containing 84
cell metastasis-related genes. Six upregulated genes and
five downregulated genes (at least 2-fold) were identified
in siATAD2-transfected Huh7 cells compared to si-negative
transfected controls (Additional file 1: Table S1). Subse-
quently, APC and CTNNA1, which showed the greatest
fold change (3-fold or more) after ATAD2 knockdown,
Figure 1 The ATAD2 expression level was higher in HCC samples and liver cancer cell lines. (a) The ATAD2 mRNA expression was up-regulated
in tumors compared to the paired nontumour patient samples. (b) IHC staining of ATAD2 in HCC. (c) Huh7 and HCCLM3 cells showed relatively higher
levels of ATAD2 expression than other liver cancer cell lines. (d) ATAD2 protein expression in each of the tumor and paired non-tumor samples was
determined by Western blotting.
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tissues by real time PCR using linear correlation statistics
(Figure 6a and b). Consistent with the results from the
real-time PCR array, the expression levels of ATAD2
and APC mRNA were negatively correlated (R2 = 0.429,
P < 0.01), and ATAD2 expression was positively correlatedFigure 2 Overall survival of HCC patients in relation to ATAD2
status. Survival of HCC patients with low ATAD2 expression versus
high expression.with CTNNA1 in HCC tissues (R2 = 0.327, P = 0.01). At
the protein level, the same trend was observed by Western
blotting (Figure 6c).Oncogenic ATAD2 was a direct downstream target for
miR-372
We found that the miR-372 expression level was lower
in HCC than in adjacent normal liver tissues (Figure 7a)
and that it was negatively correlated with ATAD2 ex-
pression (r = -0.5237, P = 0.0002; Figure 7b) by RT-qPCR.
According to prediction websites (TargetScan, PicTar and
miRanda), we searched for the target genes of miR-372
and found that ATAD2 contains one potential miR-372
binding site in its 3′ UTR (Figure 7c). This sequence is
highly conserved across different species (human, chim-
panzee, mouse, rat, pig, and rabbit) (Figure 7d). There-
fore, we constructed vectors containing the wild-type or
mutant 3′ UTR of ATAD2 fused downstream of the
firefly luciferase gene. The wild-type or mutant vector
was co-transfected into 293 T cells with a miR-372 expres-
sion construct, and the transfection efficiency was normal-
ized by co-transfection with a Renilla luciferase vector. As
shown in Figure 7e, miR-372 significantly decreased the
relative luciferase activity of the wild-type ATAD2 3′ UTR
(40%) compared to the mutant 3′ UTR, indicating
that miR-372 could directly bind to the 3′ UTR of
ATAD2. Thus, we suggest that ATAD2 is a direct target of
miR-372.
Table 2 Univariate and multivariate analyses of individual parameters for correlations with overall survival rate: Cox
proportional hazards model
Variables Univariate Multivariate
HR CI (95%) P value HR CI (95%) P value
ATAD2 1.843 1.220-2.784 0.004a 2.221 1.444-3.416 0.001a
Age 1.253 0.856-1.542 0.407
Gender 1.176 0.601-1.583 0.921
Tumor stage 1.122 0.920-1.367 0.255
HBsAg 1.150 0.792-1.670 0.464
Tumor differentiation 1.028 0.784-1.347 0.843
Metastasis 1.816 1.232-2.678 0.003a 1.822 1.221-2.718 0.003a
Tumor size 1.573 1.059-2.336 0.025a 1.909 1.276-2.855 0.002a
Serum AFP 1.670 1.110-2.512 0.014a 1.992 1.306-3.038 0.001a
Liver cirrhosis 1.056 0.640-1.429 0.827
Abbreviation: HR, Hazard Ratio; CI, Confidence Interval.
a.Statistically significant (p < 0.05).
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It was demonstrated that ATAD2 is a novel candidate
oncogene and possibly a therapeutic target for several
types of human cancer [5,7,12,16]. However, the abnormal
expression of ATAD2 and its possible carcinogenesis inFigure 3 The CCK8 assay was performed after ATAD2 siRNA treatmen
Clonogenic assays were performed with ATAD2-depleted cancer cells. The
fewer than that of control siRNA-treated cells (P < 0.05).HCC have not been studied thus far. IHC showed that
ATAD2 expression in the HCC tissues was significantly
higher than in adjacent non-tumor tissues. In addition,
the upregulation of ATAD2 was observed in the majority
of HCCs compared to their adjacent normal liver tissuest. (a) A reduction of absorbance was observed (P < 0.05). (b)
number of colonies formed by cells treated with ATAD2 siRNA was far
Figure 4 siRNA-mediated ATAD2 knockdown reduced Huh7 and HCCLM3 cell proliferation and led to a G1 phase cell cycle arrest.
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the upregulation of ATAD2 may play an important role in
HCC tumorigenesis.
Further correlation analyses indicated that the high
expression of ATAD2 in the HCC tissues was positively
correlated with tumor metastasis. These results demon-
strated that the upregulation of ATAD2 in HCC might
play an important role in promoting malignant tumors.
Similar results were also observed in other human malig-
nancies, such as esophageal, gastric, colon, and breast can-
cers [12,16], in which the overexpression of the ATAD2
gene was often observed in more aggressive tumor sub-
groups and provided diagnostic value. Furthermore, we
found that the high expression of ATAD2 in HCC was a
strong and independent predictor of shortened overall
survival.
With regard to the gene function, the bromodomain
encoded by ATAD2 contributes to the high-affinity recog-
nition of acetylated lysine [16], which is frequently found
in chromatin remodeling and histone acetylation [17]. The
bromodomain may play an important role in cell growth,
proliferation, invasion and apoptosis. In the present study,
ATAD2 protein was detectable by Western blotting in all
seven cell types studied. The Huh7 and HCCLM3 cells
had relatively higher levels of endogenous ATAD2, and
the depletion of ATAD2 by transfection with siRNA in
these two cell lines led to a G1 phase cell cycle arrest and
reduced cell growth/proliferation. In addition, siRNA-
mediated ATAD2 knockdown could significantly inhibit
cell migration and cell invasion. This result was in agree-
ment with previous studies that showed that ATAD2 wasclosely involved in several key regulatory mechanisms
to control cell proliferation or tumor metastasis through
its structure domain [18,19]. Taken together, these data
provide evidence that ATAD2 is not only important in
HCC cell proliferation but also involved in carcinoma
cell migration and invasion.
However, the molecular mechanisms by which ATAD2
regulates cancer cell proliferation and invasion remain
unclear. From the Human Tumor Metastasis RT-PCR array
with ATAD2 siRNA-treated cells, we identified APC,
ITGB3, FXYD5, ITGA7 and CTNNA1 (α-catenin), which
are related to cell adhesion; among these, the expression
of APC and CTNNA1 changed by at least 3-fold.
APC, which negatively regulates β-catenin, plays an
important role in the development of HCC. In mice
lacking APC in the liver, β-catenin was stabilized, which
significantly increased the incidence of HCC [20]. Colnot
et al. [20] found that 67% of APC(lox/lox) mice developed
HCC when Cre adenovirus was injected. The β-catenin
signaling in these mice was strongly activated, indicating
that the loss of APC function led to Wnt signaling
pathway activation and caused the occurrence of tumors.
CTNNA1 functions in a complex with CTNNB1, where
it acts to tether the cytoplasmic domain of E-cadherin to
the cytoskeleton [21,22]. Vasioukhin et al. found that inhi-
biting CTNNA1 destablizes adherens junctions, which
weakens the interaction between cells and makes them
less sensitive to contact-mediated inhibition [23]. Previous
studies showed that reduced CTNNA1 expression in some
solid tumors may be associated with increased malignant
behavior [24-26]. However, some studies showed that
Figure 6 APC and CTNNA1 expression was associated with ATAD2 in 45 HCC tissues. (a) Real-time PCR results showed ATAD2 and APC ex-
pression was negatively correlated in HCC tissues (P < 0.01). (b) ATAD2 expression was positively correlated with CTNNA1 (P < 0.01). (c) At the pro-
tein level, the same trend was observed by Western blotting.
Figure 5 Transwell assays of Huh7 and HCCLM3 cells transfected with control and ATAD2 siRNA. (a). ATAD2 depletion had a measurable
inhibitory effect on cell invasion in both cell lines. (b). The numbers of invading cells were counted, and a significant difference was observed
(*P < 0.05). (c). A significant difference was observed in both cell lines and (d) the numbers of migrating cells were counted (*P < 0.05).
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Figure 7 The relationship between miR-372 and ATAD2. (a) Significant down-regulation of miR-372 in paired HCC/NT samples was defined
as a log2-fold change < −1. (b) miR-372 expression was negatively correlated with ATAD2 expression in 45 paired samples. (c) Luciferase assay
with wild-type and miR-372 binding site-mutated ATAD2-3′ UTR in the presence of a miR-372 expression plasmid. Mutations are underlined and
italicized. (d) miR-372 binding site in the ATAD2 3′ UTR in different species. The seed sequence is under the white box. (e) Relative luciferase
activity analyses. The relative luciferase activity of the pGV214 group was set as 1.
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entiated HCC than in well-differentiated HCC [27,28].
CTNNA1 and CTNNB1 link cadherins to the cytoskel-
eton at epithelial cell-cell adherens junction complexes
[29]. As is well known, in addition to the formation of the
E-cadherin-catenin complex, CTNNB1 is associated with
the Wnt/Wingless signal transduction pathway and binds
to APC, EGFR and the c-erbB2 proto-oncogene. Thus,
whether ATAD2 could affect APC and CTNNA1 to foster
tumorigenesis by activating the WNT pathway is a goal
for further research.
In the present study, we detected changes in the ex-
pression of two genes—upregulated APC and down-
regulated CTNNA1—after knocking down ATAD2 in
Huh7 cells, and we validated these changes at the protein
level by Western blotting. It appears that in our HCC
cells, ATAD2 regulates cell migration/invasion via the
regulation of APC and/or CTNNA1 expression. Through
real time PCR detection in 45 paired tissue samples, wealso found that ATAD2 was significantly negatively corre-
lated with APC and CTNNA1 expression.
Moreover, we also studied the upstream mechanism
regulating ATAD2 expression in HCC. miR-372 belongs
to the miR-371-373 gene cluster that also includes miR-93
and miR-302a [30]. These microRNAs play an important
role in the development of many types of human malignant
tumors. One report noted that miR-372 is an oncogene in
human glioma; it is more highly expressed in glioma cells
than in normal brain cells and is closely related to the
prognosis of glioma [31]. In the gastric cancer cells, Cho
et al. found that miR-372 could promote cell proliferation
and inhibit apoptosis; these biological roles are caused by
acting on the downstream LATS2 gene [32]. LATS2, which
is an important tumor suppressor, plays an important role
in inhibiting cell proliferation in gastric cancers. In the
present study, we found that miR-372 was negatively cor-
related with ATAD2. Through the luciferase reporter gene
assay, we further confirmed that the ATAD2 mRNA 3′
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miR-372. More work is necessary to understand how
miR-372 regulates ATAD2 expression.
Conclusions
In summary, we provided a basis for the concept that the
high expression of ATAD2 in HCC may be important in
the acquisition of an aggressive phenotype and indicate a
poor prognosis for HCC patients. Furthermore, the func-
tional studies of ATAD2 in this report suggest a potential
role of ATAD2 in affecting cell proliferation, invasion, and
migration and make ATAD2 an attractive target for future
cancer therapeutics.
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